TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03564457

Intervention type: OTHER
Intervention: No interventions will take place (observational)
Description: No interventions will take place (observational)
Study: NCT00661193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: given IV
Study: NCT02668575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care Intervention
Description: Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
Study: NCT00858273

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant supplement
Description: 1 capsule daily with dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant supplement
Description: 1 capsule daily with dinner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes treatment
Description: Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes treatment
Description: Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular Insulin
Description: Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
Study: NCT05579457

Intervention type: OTHER
Intervention: Short Physical Performance Battery
Description: The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance

Intervention type: OTHER
Intervention: Short Physical Performance Battery
Description: The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance
Study: NCT02390947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: 25 mg p.o. qd
Study: NCT03719313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG IFN-alfa-2a
Description: PEG IFN alfa-2a 180 mcg QW
Study: NCT01847989

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
Study: NCT03914755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered via oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered via oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered via oral tablet
Study: NCT00026312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04548804

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG-Imaging
Description: A body surface potential mapping and a cardiac + low dose CT-scan
Study: NCT03719313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG IFN-alfa-2a
Description: PEG IFN alfa-2a 180 mcg QW
Study: NCT00026312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02820909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous and arterial catheter set-up using ultrasound guidance
Description: The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical guidance.
Description: In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (\> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
Study: NCT01566383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-hr pH monitoring
Description: Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device
Study: NCT00608959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omiganan 1% gel
Description: Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine 2% solution
Description: Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only.
Study: NCT03206398

Intervention type: DEVICE
Group type: OTHER
Intervention: anti-gravity treadmill
Description: anti-gravity treadmill for a total of 40 days in addition to physiotherapy
Study: NCT02198105

Intervention type: DEVICE
Intervention: Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA
Description: Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil \>30%~2. no dissection \>Type B~3. no stenting \>30% of lesion length.
Study: NCT01933776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap
Description: 0.5 mL, Intramuscular (IM)
Study: NCT00026312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00026312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given IV or SC
Study: NCT04218318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.
Study: NCT04542616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation
Description: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
Study: NCT02681692

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic endoscopic imaging system
Description: In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic endoscopic imaging system
Description: In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
Study: NCT04142697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heading direction adaptation
Description: Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heading direction adaptation
Description: Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
Study: NCT03569241

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole pelvic radiotherapy
Description: addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: salvage Lymph Node Dissection
Description: metastasis-directed treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salvage Lymph Node Dissection
Description: metastasis-directed treatment

Intervention type: DRUG
Group type: OTHER
Intervention: androgen deprivation therapy
Description: LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
Study: NCT04511533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib is a kinase inhibitor indicated for the first line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
Study: NCT05150392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.And the live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Study: NCT01546909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, polio and pertussis vaccination
Description: 1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
Study: NCT02146911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Motivational Emails
Description: The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Motivational Emails
Description: The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
Study: NCT04409262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Participants will receive intravenous (IV) RDV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Participants will receive intravenous (IV) RDV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV TCZ
Study: NCT02390947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg p.o. qd
Study: NCT04006002

Intervention type: OTHER
Intervention: Metabolic and Hormonal profile
Description: To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention

Intervention type: OTHER
Intervention: Metabolic and Hormonal profile
Description: To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
Study: NCT01459783

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia care management
Description: Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia care management
Description: Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
Study: NCT03435471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic Swallowing Home Exercise Program
Description: The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
Study: NCT04269356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk of magnesia
Description: Specified dose on specified days
Study: NCT01331109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
Study: NCT00066963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: 0.1 mL (1 drop) applied on each of 2 arches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: 0.1 mL (1 drop) applied on each of 2 arches
Study: NCT04543292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MATFILL (PTFE)
Description: Filling of the prosthetic chimney with the compressed material
Study: NCT00988091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1.2% Sodium Hyaluronate
Description: IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Buffered Saline
Description: IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
Study: NCT01111344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen + Viusid
Description: Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~* 1 to 3.9 cm2 ______________3 daily applications~* 4 to 6.9 cm2 ______________4 daily applications~* 7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion.